Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в січні 1993 (uk)
- im Januar 1993 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en xineru de 1993 (ast)
- artikull shkencor i botuar më 01 janar 1993 (sq)
- scientific article published on 01 January 1993 (en)
|
publication date
| |
publication date
| |
language of work or name
| |
language of work or name
| |
author name string
| |
author name string
| - W P Steward
- J Verweij
- P Kerbrat
- T Tursz
- D Crowther
- D Spooner
- M Clavel
- R Somers
- J Rouesse
- E Tueni
|
rdfs:label
| - Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom (en)
- Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom (nl)
- Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom (sq)
|
skos:prefLabel
| - Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom (en)
- Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom (nl)
- Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom (sq)
|
name
| - Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom (en)
- Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom (nl)
- Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom (sq)
|
title
| |
title
| - Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (en)
|
page(s)
| |
page(s)
| |
instance of
| |
instance of
| |
main subject
| |
main subject
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
issue
| |
volume
| |
issue
| |
volume
| |
DOI
| |
DOI
| |
DOI
| |
is about
of | |
is cites work
of | - Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide?
- Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients
- Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study
- Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review
- High-dose chemotherapy in adult soft tissue sarcoma
- Soft tissue sarcomas--what is currently being done
- Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?
- Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma
- The role of hematopoietic growth factors in transfusion medicine.
- Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial
- Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide
- Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
- Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group
- Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma
- Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma
- Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK)
- Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial
- The management of adult soft tissue sarcomas
- Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach
- An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma
- Diagnosis and treatment of soft tissue tumours: the dutch nationwide-accepted consensus
- Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?
- Adjuvant chemotherapy for extremity soft-tissue sarcomas in adults
- A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
- Soft tissue tumours
- Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study
- Adipogenesis induces growth inhibition of dedifferentiated liposarcoma
- Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study
- The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience
- Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS)
- Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline
- Etoposide for soft tissue sarcomas: fact or fiction
- Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study
- Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
- The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas
- Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients
|
is cites work
of | |